Barclays lowered the firm’s price target on Kura Oncology (KURA) to $11 from $32 and keeps an Overweight rating on the shares post the Q1 report. The firm “de-risking” the model but says Kura’s key catalysts are on track.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology Advances with Key NDA Submission
- Kura Oncology: Promising Clinical Trial Results and Strong Financial Position Support Buy Rating
- Kura Oncology’s Promising Future: Strong Financial Health and Successful Clinical Trials Drive Buy Rating
- Kura Oncology reports Q1 EPS (66c), consensus (60c)
- Kura Oncology (KURA) Q1 Earnings Cheat Sheet